Grifols pauses Canadian plasma collection
Analysis based on 6 articles · First reported Aug 13, 2026 · Last updated Aug 14, 2026
The temporary closure of Grifols' Canadian plasma collection operations may reduce its revenue from that segment and raise regulatory and reputational concerns, potentially affecting its stock price. However, the impact on Canada's blood supply is expected to be minimal, and the company may resume operations after addressing compliance issues.
Grifols, a Spain-based for-profit plasma donation company, announced on August 13, 2026, that it would temporarily pause plasma collection at all its Canadian clinics. The decision came amid public scrutiny and regulatory pressure following the deaths of two donors at its Canada — Winnipeg clinics, including Rodiyat Alabede, and a Canada — Health Canada inspection that found multiple compliance issues. Canada — Health Canada issued a non-compliance rating for Grifols' Taylor Avenue site in Canada — Winnipeg and had previously imposed conditions on more than a dozen sites. Grifols stated the pause was due to 'unfounded attention' and that it would work with Canada — Health Canada and Canadian Blood Services to address concerns. Canada — Health Canada welcomed the decision, stating it would not impact Canada's blood supply. Advocacy groups, including the Manitoba Health Coalition, have called for a ban on paid plasma donations, citing a pattern of poor practices. Grifols maintains that donor safety has never been compromised.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard